Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Loss per Share

Note 7 - Loss per Share

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 7 - Net Loss Per Share

Basic and diluted net loss per common share was calculated as follows:

	*Three Months Ended September 30,*						*Nine Months Ended September 30,*
(in thousands, except for net loss per share)	*2024*			*2023*			*2024*			*2023*
Numerator:
Net loss	$	(1,304	)	$	(1,954	)	$	(4,661	)	$	(6,588	)

Denominator:
Weighted-average common shares outstanding, basic and diluted^**		3,520			2,824			3,419			2,710

Net loss per common share, basic and diluted	$	(0.37	)	$	(0.69	)	$	(1.36	)	$	(2.43	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share
Stock options to purchase common stock^**		429			423			429			423
Unvested restricted stock units^**		48			106			48			106

^**Information pertaining to number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.